Long-term survival in multiple myeloma: a single-center experience.
In patients with multiple myeloma the median overall survival is now approaching 5 years, following the introduction of autologous stem cell transplantation and targeted therapies. However, patients receiving conventional chemotherapy who have survived 10 years or longer have been repeatedly reported in the literature. From 723 patients with multiple myeloma seen in our department from January 1981 to June 2007, we selected 21 long-term (> or =10 years) survivors (2.9%) who had been treated with conventional chemotherapy. Potentially favourable prognostic factors, common to most patients, were: age < or =65 years; response to first-line chemotherapy; absence of Bence-Jones proteinuria; prolonged duration of response or stable disease irrespective of the primary regimen; maintenance therapy with interferon-alpha. The use of prognostic factors to identify a subset of low-risk patients could be of assistance in the selection of targeted treatments and the elucidation of poorly known features of myeloma biology.
Merchionne
Francesca
F
Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine and Clinical Oncology, University of Bari Medical School, Piazza Giulio Cesare 11, Bari, Italy.
Procaccio
Pasquale
P
Dammacco
Franco
F
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000503:physiopathology*; D011379:Prognosis; D013534:Survival
D000970:Antineoplastic Agents
Blood. 1993 Mar 15;81(6):1428-34
8453092
J Clin Oncol. 2005 May 20;23(15):3412-20
15809451
J Clin Oncol. 2004 May 15;22(10):1857-63
15111617
Eur J Haematol. 1999 Feb;62(2):109-16
10052714
Br J Haematol. 2001 Jun;113(4):1020-34
11442498
Blood. 2003 Nov 1;102(9):3340-8
12855563
Br J Haematol. 1996 May;93(2):345-51
8639427
Cancer. 1972 Aug;30(2):382-9
5051662
N Engl J Med. 2003 Dec 25;349(26):2495-502
14695409
J Clin Invest. 1994 Dec;94(6):2317-25
7989587
Eur J Haematol. 2000 Sep;65(3):175-81
11007053
Blood. 1999 May 1;93(9):3064-73
10216103
J Clin Oncol. 2007 Jun 10;25(17):2434-41
17485707
Blood Rev. 1994 Mar;8(1):13-20
8205006
Br J Haematol. 1990 Nov;76(3):365-8
2261347
Br J Haematol. 1998 Sep;102(5):1115-23
9753033
Ann Hematol. 1998 Feb;76(2):67-72
9540760
N Engl J Med. 1996 Jul 11;335(2):91-7
8649495
Eur J Haematol. 2005 Nov;75(5):370-5
16191085
JAMA. 1969 Jun 2;208(9):1680-5
5818682
N Engl J Med. 2005 Jun 16;352(24):2487-98
15958804
J Immunol. 1991 Dec 15;147(12):4402-7
1753108
Eur J Cancer. 2006 Jul;42(11):1564-73
16765041
N Engl J Med. 1990 May 17;322(20):1430-4
2184356
N Engl J Med. 1983 Feb 10;308(6):314-6
6823231
Br J Haematol. 2003 Apr;121(2):251-8
12694246
Br J Haematol. 1994 Aug;87(4):832-4
7986723
Blood. 2005 Dec 15;106(13):4050-3
16118317
Acta Haematol. 2001;105(4):241-3
11528099
Eur J Cancer. 2003 Jan;39(1):31-7
12504655
J Clin Oncol. 2006 Jan 20;24(3):431-6
16365178
Haematologica. 2007 Oct;92(10):1399-406
18024376
J Intern Med. 1992 Feb;231(2):129-31
1541934
Cancer. 1984 May 15;53(10):2069-72
6704893
Arch Intern Med. 1985 Nov;145(11):2073-4
4062460
Ann Oncol. 2000 Nov;11(11):1427-36
11142483
Cancer. 1975 Sep;36(3):842-54
1182674
J Clin Oncol. 2007 May 20;25(15):1993-9
17420512
Cancer Treat Rep. 1984 Nov;68(11):1331-8
6388832
Br J Haematol. 2006 May;133(4):389-96
16643445
Haematologica. 1999 Apr;84(4):336-41
10190948
Br J Haematol. 1998 Jul;102(2):495-502
9695964
Eur Cytokine Netw. 1990 Oct-Nov;1(4):193-201
2104241
J Clin Oncol. 1998 Dec;16(12):3832-42
9850028